1. Home
  2. QFIN vs PHVS Comparison

QFIN vs PHVS Comparison

Compare QFIN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qifu Technology Inc.

QFIN

Qifu Technology Inc.

HOLD

Current Price

$12.33

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$27.40

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QFIN
PHVS
Founded
2016
2015
Country
China
Switzerland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
QFIN
PHVS
Price
$12.33
$27.40
Analyst Decision
Strong Buy
Buy
Analyst Count
3
10
Target Price
$32.37
$40.70
AVG Volume (30 Days)
1.4M
134.2K
Earning Date
03-17-2026
05-12-2026
Dividend Yield
12.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.60
$11.51
52 Week High
$46.18
$29.80

Technical Indicators

Market Signals
Indicator
QFIN
PHVS
Relative Strength Index (RSI) 28.63 52.71
Support Level N/A $24.25
Resistance Level $14.63 $28.06
Average True Range (ATR) 0.57 1.23
MACD -0.07 0.11
Stochastic Oscillator 0.00 69.23

Price Performance

Historical Comparison
QFIN
PHVS

About QFIN Qifu Technology Inc.

Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: